Drug Pricing Reforms And Patent Expiry Will Constrain Outcomes
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 26 Analysts
Published
04 May 25
Updated
09 Aug 25
AnalystLowTarget's Fair Value
US$650.00
7.9% overvalued intrinsic discount09 Aug
US$701.23
1Y
-24.0%7D
12.1%